26 /100
MEDIUM RISK
Score updated Jul 14, 2026

SYRA — Syra Health Corp. Dilution Risk Tracker

Track SYRA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SYRA — Get alerts when the score changes →

As of July 14, 2026, Syra Health Corp. (SYRA) has a DilutionWatch DilutionScore of 26/100, rated MEDIUM dilution risk. Syra Health Corp. has a market capitalization of $6.57M, 11.34M shares outstanding, 1 institutional holders tracked. Key dilution vectors include approximately 999 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
36
💰 Cash Runway
0
📊 Float Risk
15
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
39%
🔄 Reverse Split 55%
• 50-day avg $0.39 below $1 exchange minimum
🔁 Convertible Conversion 40%
• Significant convertible debt: 22% potential dilution
• Elevated convertible risk (60/100)
🔔 Track SYRA — Get forecast alerts →

💹 Market Data

Market Cap$6.57M
Shares Outstanding11.34M
FloatN/A
Cash$2.92M
DebtN/A
Short InterestN/A

🏛 Institutional Holdings

1 institutional holders · 231 shares
#1 BARCLAYS PLC 231 shares

📉 Short Interest

Short Interest110.4K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Sep 30, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2023
4 INSIDER TRANSACTION Feb 03, 2026
3 FORM3 Jan 14, 2026
3 FORM3 Jan 13, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for SYRA Shareholders

Syra Health Corp. (SYRA) has a DilutionScore of 26/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for SYRA shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for SYRA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for SYRA alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track SYRA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking SYRA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for SYRA
📊 SYRA FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 SYRA Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.